We are live on ! Find out more
AVEO

AVEO Pharmaceuticals, Inc.

Delisted

AVEO was delisted on the 19th of January, 2023.

61 hedge funds and large institutions have $42.3M invested in AVEO Pharmaceuticals, Inc. in 2014 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 12 increasing their positions, 26 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

3% more capital invested

Capital invested by funds: $41.2M → $42.3M (+$1.12M)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

10% less funds holding

Funds holding: 6861 (-7)

38% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 16

54% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 26

91% less call options, than puts

Call options by funds: $7K | Put options by funds: $81K

Holders
61
Holders Change
-7
Holders Change %
-10.29%
% of All Funds
1.75%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.09%
New
10
Increased
12
Reduced
26
Closed
16
Calls
$7K
Puts
$81K
Net Calls
-$74K
Net Calls Change
-$52K
Name Holding Trade Value Shares
Change
Change in
Stake
Deutsche Bank
26
Deutsche Bank
Germany
$237K -$393K -30,185 -70%
LP
27
LMR Partners
United Kingdom
$205K +$146K +11,231 New
Tudor Investment Corp
28
Tudor Investment Corp
Connecticut
$195K
Group One Trading
29
Group One Trading
Illinois
$152K +$38.3K +2,941 +55%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$121K -$217K -16,693 -72%
CS
31
Credit Suisse
Switzerland
$121K +$48.6K +3,739 +130%
Connor, Clark & Lunn Investment Management (CC&L)
32
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$107K -$1.69K -130 -2%
NCCM
33
Nine Chapters Capital Management
New Jersey
$99K +$44.6K +3,430 +172%
Susquehanna International Group
34
Susquehanna International Group
Pennsylvania
$97K +$49.3K +3,787 +250%
CCMH
35
Cornerstone Capital Management Holdings
New York
$91K -$58.7K -4,510 -47%
SFM
36
Soros Fund Management
New York
$90K +$63.8K +4,908 New
SKK
37
Shepherd Kaplan Krochuk
Massachusetts
$88K -$11.7K -900 -16%
Barclays
38
Barclays
United Kingdom
$86K +$109K +8,413 +3,824%
Morgan Stanley
39
Morgan Stanley
New York
$82K +$28.7K +2,206 +97%
SIM
40
Spark Investment Management
New York
$72K +$51.9K +3,990 New
Two Sigma Investments
41
Two Sigma Investments
New York
$63K -$62K -4,769 -58%
BCM
42
Bridgeway Capital Management
Texas
$55K +$39K +3,000 New
State Street
43
State Street
Massachusetts
$53K -$950K -73,067 -96%
GC
44
Guggenheim Capital
Illinois
$42K -$12.9K -991 -30%
BA
45
BlackRock Advisors
Delaware
$39K -$109K -8,364 -80%
EWM
46
Evercore Wealth Management
New York
$39K +$11K +848 +66%
Charles Schwab
47
Charles Schwab
California
$28K -$84.4K -6,490 -81%
AG
48
Aperio Group
California
$25K -$53.4K -4,105 -75%
FCI
49
Financial Counselors Inc
Kansas
$24K
EWM
50
Edge Wealth Management
New York
$18K

AVEO Hedge Fund Activity: Q2 2014 in Review

61 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q2 2014, worth a combined $42.3M — up 2.7% from $41.2M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of AVEO and 10 opened new positions — a net loss of 6 holders — while 26 trimmed existing stakes and 12 added.

The largest buyer was Fore Research & Management, opening a new position worth an estimated $877K. The largest seller was BlackRock Fund Advisors, cutting an estimated $1.67M.

  • 61 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q2 2014, down from 68 in Q1 2014.
  • Funds reported $42.3M of AVEO Pharmaceuticals, Inc. stock for Q2 2014, up 2.7% quarter-over-quarter.
  • 10 funds opened new AVEO Pharmaceuticals, Inc. positions in Q2 2014 and 16 closed out, a net change of -6 holders.
  • The largest AVEO Pharmaceuticals, Inc. buyer in Q2 2014 was Fore Research & Management, an estimated $877K added.
  • The largest AVEO Pharmaceuticals, Inc. seller in Q2 2014 was BlackRock Fund Advisors, an estimated $1.67M sold.

Based on aggregated 13F filings for Q2 2014.